

Original article

Socio-demographic determinants in the evolution of pain in inflammatory rheumatic diseases: results from ESPOIR and DESIR cohorts

Sushmithadev Kumaradev ^{1,2}, Christian Roux^{1,3}, Jérémie Sellam⁴, Serge Perrot⁵, Thao Pham⁶, Aline Dugravot^{2,*} and Anna Molto^{1,3,*}

Abstract

Objective. To determine whether socio-demographic factors are associated with heterogeneity in pain evolution in inflammatory rheumatic diseases (IRDs) after accounting for disease-specific characteristics in a system with universal health care.

Methods. This analysis included the data from two prospective observational cohorts of early IRDs (ESPOIR for early RA and DESIR for early SpA). Data on pain was measured, respectively, on 13 and 9 occasions spanning 10 and 6 years of follow-up using the Short-Form 36 bodily pain score for 810 participants of ESPOIR, and 679 participants of DESIR. Linear mixed models were used to characterize differences in pain evolution as a function of age (tertiles), sex, ethnicity, education, marital, and professional status, after accounting for disease-related, treatment, lifestyle, and health factors.

Results. While transitioning from early (disease duration ≤ 6 months for RA and ≤ 3 years for SpA) to long-standing disease, differences in pain evolution emerged as a function of age ($P < 0.001$), sex ($P = 0.050$), and ethnicity ($P = 0.001$) in RA, and as a function of age ($P = 0.048$) in SpA; younger age, males, and Caucasians exhibited lower pain in the latter phases of both diseases. Highly educated participants (RA, $\beta = -3.8$, $P = 0.007$; SpA, $\beta = -6.0$, $P < 0.001$) for both diseases, and Caucasians ($\beta = -5.6$, $P = 0.021$) for SpA presented with low pain early in the disease, with no changes throughout disease course.

Conclusion. Being older, female, non-Caucasian and having lower education was found to be associated with worse pain in early and/or long-standing IRDs, despite universally accessible health-care. Early identification of at-risk populations and implementation of multidisciplinary strategies may reduce patient-reported health outcome disparities.

Trial registration registrations. ESPOIR: ClinicalTrials.gov, www.clinicaltrials.gov, NCT03666091. DESIR: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01648907.

Key words: pain evolution, rheumatoid arthritis, spondyloarthritis, socio-demographic factors, pain outcome

Rheumatology key messages

- Socio-demographic characteristics were associated with interindividual heterogeneity in experience of pain in both early and long-standing inflammatory rheumatic diseases.
- Low education impacted pain at or before disease onset; demographic traits impacted pain temporally after the onset of disease and throughout its course.
- Multidisciplinary treatment of pain should start early in disease, targeting those with worse pain outcomes.

¹Clinical Epidemiology Applied to Rheumatic and Musculoskeletal Diseases, ²Epidemiology of Ageing and Neurodegenerative Diseases, Inserm 1153, Université de Paris, ³Department of Rheumatology, APHP-Centre, Cochin Hospital, ⁴Department of Rheumatology, APHP-Centre, Saint-Antoine Hospital, ⁵Pain Clinic, APHP-Centre, INSERM U897, Cochin Hospital, Paris and ⁶Department of Rheumatology, APHM, Sainte-Marguerite Hospital, Aix-Marseille Univ, Marseille, France

Submitted 23 February 2021; accepted 30 May 2021

Correspondence to: Sushmithadev Kumaradev, Université de Paris, Inserm U1153 EpiAgeing, 10 Avenue de Verdun, 75010 Paris, France. E-mail: sushmithadev.kumaradev@inserm.fr

*Aline Dugravot and Anna Molto contributed equally to this study.

Introduction

Pain mechanisms in inflammatory rheumatic diseases (IRDs) are multifactorial and are broadly classified as inflammatory (related to disease pathophysiology) and non-inflammatory (attributed to dysregulation of peripheral and central pain-conducting pathways) [1, 2]. The pattern of pain evolution in IRDs is characterized by prominently decreasing pain in the early phases, probably due to early diagnosis and treatment, followed by pain plateauing in the ensuing years [3, 4] at a level higher than the population average [5, 6]. Emerging findings suggest that pain course is not uniform to all; unresolving pain probably linked to non-inflammatory mechanisms was observed among subgroups of those with IRDs, despite optimally controlled inflammation and universally accessible health-care advances [7]. In addition to disease severity [8, 9], the treatment initiated [10] and individuals' lifestyle and psychological health, it has been found that socio-demographic characteristics potentially contribute about 5–11% of the observed pain heterogeneity in IRDs [11, 12]; older age [13, 14], female sex [15–18], non-Caucasian ethnicity [19] and low socio-economic status [20] are associated with increased pain in IRDs; however, the consistency of this association throughout the disease course is unknown. Previous studies reporting associations between socio-demographic characteristics and pain in IRDs were based on cross-sectional [21, 22] or longitudinal design that either did not account for non-linear evolution of pain in IRDs [11], were not based on repeatedly assessed pain measures [23], or were limited to patients with early [18] or long-standing disease [13, 14]. The aforesaid studies may have missed relevant information about temporal changes in pain associated with the transition from early to long-standing IRDs. Fluctuations in disease-specific characteristics, response to treatment, health, and pain coping behaviours accompanying disease-phase transitioning, could modify the effect of socio-demographic characteristics on pain evolution. For instance, prospective studies on early RA found that sex differences in pain were often apparent during the course of the disease [24, 25] and not before 6 months since symptom onset [18, 26], highlighting the importance of assessing temporal trends in pain. Thus, exploring the impact of socio-demographic characteristics on pain while transitioning from early to long-standing IRDs can help the understanding of pain behaviour among vulnerable groups, and the implementation of appropriate treatment strategies quite early in disease course. Accordingly, this study aimed to assess the evolution of pain in IRDs as a function of socio-demographic characteristics, after accounting for disease-specific, current treatment, lifestyle, and psychological and health factors using repeated measures since disease onset for up to 6 years or longer.

Methods

Study design and participants

The participants of this study belong to the two ongoing prospective French multicentric cohorts in a setting of universally accessible health-care: ESPOIR (Etude et Suivi des Polyarthrites Indifférenciées Récentes) [27] started in 2002/2005 and DESIR (DEvenir des Spondylarthropathies Indifférenciées Récentes) [28] started in 2007/2010. ESPOIR comprises 813 participants aged 18–70 years with features suggestive of early RA of <6 months duration followed up over 10 years. DESIR comprises 708 participants aged 18–50 years, presenting with inflammatory back pain with a highly probable SpA diagnosis, for a duration ranging from 3 months to 3 years followed up for 6 years. Participants were biologic DMARDs naïve at inclusion. Clinical visits were conducted biannually in the initial 2 years of follow-up and annually henceforth, corresponding to 13 and 9 visits, respectively, for ESPOIR and DESIR cohorts, collecting clinical, biological and radiographic information. The study was conducted as per good clinical practice guidelines. Cohort ESPOIR obtained ethical approval from the ethics committee of Montpellier, France (no. 020307), and cohort DESIR obtained ethical approval from Comité de Protection des Personnes Ile de France III. Signed informed consent was given by the participants of both cohorts.

Pain

The bodily pain subscale of the 36-item short-form questionnaire (SF-36 BP) was used as a valid measure for pain evaluation [29, 30]. In both the cohorts, the SF-36 BP comprises two questions evaluating pain intensity and interference “over last 8 days”. (Refer to the [Supplementary Data S1](#), available at *Rheumatology* online, regarding the SF-36 BP component questions and scoring pattern.) Both pain intensity and interference scores were averaged to obtain SF-36 BP. To ease interpretation, the scores were reversed so that higher scores corresponded to higher pain. Apart from SF-36 BP, a visual analogue scale [30, 31] measure ranging from 0 (no pain) to 100 (worst imaginable pain), measuring joint pain intensity when mobilized (joint mobilization pain) and when at rest (resting joint pain) for ESPOIR, and a numerical rating scale [31] ranging from 0 (no pain) to 10 (worst imaginable pain) measuring back pain intensity during the day (back pain) and at night (night pain) for DESIR were also considered. Numerical rating scale scores were multiplied by 10 to assure uniformity in the range of pain measures (0–100) across the different scales. Pain variables were assessed at each clinical visit.

Socio-demographic factors

Demographic factors included sex, age at inclusion (continuous, tertiles) and ethnicity (participants self-identified themselves as Caucasians or Others—those

belonging to African, Asian, Maghrebian, or other origin). Social factors included education, and marital and professional status as recorded at inclusion. The highest attained education was categorized as low education (less than or equal to secondary level) or high education (more than secondary level). Marital status was categorized as couples (married or cohabiting) or single (unmarried, divorced and widowed). Professional status was classified as no job (those without a job or retired), or blue-collar (labourers, farmers or artisans), and white-collar (intermediate and executive professional) workers.

Covariates

Disease-related factors included symptom duration and a distinct set of variables for each cohort. Variables for ESPOIR were: inflammatory marker (ESR in mm/h), clinical markers (tender, and swollen joint count based on 28 joints), imaging marker (presence of X-ray changes fulfilling ACR 1987 criteria) [32], and biological markers (RF and ACPA positivity). Variables for DESIR were: inflammatory marker (CRP in mg/dl), clinical markers [history of peripheral arthritis (arthritis index), history of peripheral enthesitis (enthesitis index), and number of swollen joints (synovitis index)], imaging marker (presence of sacroiliitis in MRI) and biological marker (HLA B27 positivity). The rationale behind the choice of disease-related factors is given in the supplement (Supplementary Data S2, available at *Rheumatology* online). Treatment included current use of NSAIDs, CSs, DMARDs and analgesics. Lifestyle factors included BMI, current smoking, and alcohol consumption status. Health factors included the rheumatic disease comorbidity index (RDCI), a validated and weighted comorbidity index for rheumatological outcomes [33] based on self-declared disease status or medication use history for lung, cardiovascular, fracture, depression (as a measure of psychological health), diabetes, cancer, and gastrointestinal diseases. (Refer to Supplementary Data S3, available at *Rheumatology* online, for RDCI calculation.) All covariates were assessed repeatedly at clinical visits and analysed as time-dependent variables whenever feasible.

Statistical analysis

Descriptive statistics comparing population characteristics by tertiles of each pain score were determined using Pearson's χ^2 , Fischer's exact and analysis of variance (ANOVA) tests. Both cohorts were analysed separately, using linear mixed models with continuous pain variables as dependent variables and time since inclusion (t_0) as timescale. Based on cubic spline regression, time, time², and time³ (slope terms) were incorporated to model non-linear evolution of pain. Random effects for the intercept and time allowed individual differences in pain score at intercept and changes in pain over time. Five multivariate models

were examined. Model 1 was adjusted for socio-demographic characteristics and their interaction with time (slope terms). Thereafter, model 1 was additionally and sequentially adjusted for disease-related (model 2), treatment (model 3), lifestyle (model 4), and health (model 5) factors. Differences in the evolution of pain as a function of socio-demographic factors were tested by examining whether interaction of socio-demographic factors with slope terms ($P_{\text{trajectory}}$) improved model fit using the Wald test. Additionally, the above analysis was repeated restricting the analytic sample to those fulfilling the ACR 1987 criteria in the ESPOIR cohort and the American SpondyloArthritis international Society (ASAS) criteria in the DESIR cohort as a part of sensitivity analysis. All analysis was performed using Stata version 15.0 (Stata Corp.). All $P < 0.05$ were considered significant.

Results

Eight hundred and ten of 813 ESPOIR participants and 679 of 708 DESIR participants having at least one measure for all variables constituted the analytic sample (Supplementary Fig. S1, available at *Rheumatology* online). The retention rates of the participants at the end of 5 years of follow-up were 61.7% and 58.2%, and at the end of follow-up were 53.5% and 43.4%, respectively, for ESPOIR and DESIR; 74.9% of ESPOIR and 58.2% of DESIR participants had data collected in at least 7 visits/waves for all variables considered for analysis. Table 1 shows the baseline characteristics of the analytic sample of both cohorts. ESPOIR participants were more likely older (ESPOIR vs DESIR mean age 48.1 vs 33.6 years, $P < 0.001$), predominantly female (76.8% vs 54.8%, $P < 0.001$), less educated (68.4% vs 39.9%, $P < 0.001$) and had higher pain scores (mean SF-36 BP 62.2 vs 56.7, $P < 0.001$) than DESIR participants. Interaction terms assessing the role of disease-related factors (inflammatory and clinical markers) in the evolution of pain (SF-36 BP) within socio-demographic groups (sex, ethnicity, and education) were not significant ($P_{\text{interaction}} > 0.07$).

Supplementary Tables S1 (ESPOIR) and S4 (DESIR), available at *Rheumatology* online, compare the baseline characteristics of participants by the tertiles of SF-36 BP at inclusion. In ESPOIR, participants with higher SF-36 BP had lower education, used analgesics more frequently and had higher ESR, tender and swollen joint counts, BMI, and RDCI. In DESIR, across SF-36 BP tertiles an increasing percentage of non-Caucasians, low education, CS and analgesic use, and increasing CRP, peripheral arthritis, and enthesitis were seen. The results for joint mobilization, and resting joint pain of ESPOIR (Supplementary Tables S2 and S3, available at *Rheumatology* online) and back and night pain of DESIR (Supplementary Tables S5 and S6, all available at *Rheumatology* online) are provided in the Supplementary Data.

TABLE 1 Baseline characteristics of RA (ESPOIR) and SpA (DESIR) cohorts

Variables	RA (ESPOIR, N = 794)	SpA (DESIR, N = 642)
Socio-demographic factors		
Male, <i>n</i> (%)	184 (23.2)	290 (45.2)
Age, <i>m</i> (s.d.), years	48.1 (12.6)	33.6 (8.6)
Caucasian, <i>n</i> (%)	733 (92.3)	577 (89.9)
More than secondary education, <i>n</i> (%)	251 (31.6)	386 (60.1)
Profession, no job, <i>n</i> (%)	32 (4.0)	89 (13.9)
White-collar workers, <i>n</i> (%)	158 (19.9)	90 (14.0)
Blue-collar workers, <i>n</i> (%)	604 (76.1)	463 (72.1)
Married, <i>n</i> (%)	579 (72.9)	418 (65.1)
Disease-related factors		
Symptom duration, <i>m</i> (s.d.), years	0.6 (0.7)	1.5 (0.9)
Inflammatory markers		
ESR, <i>m</i> (s.d.)	29.4 (24.7)	
CRP, <i>m</i> (s.d.)		7.5 (13.0)
Clinical markers		
Tender joint count (0–28), <i>m</i> (s.d.)	8.4 (7.0)	
Swollen joint count (0–28), <i>m</i> (s.d.)	7.2 (5.4)	
Arthritis index (0–159), <i>m</i> (s.d.)		4.2 (8.2)
Synovitis index (0–28), <i>m</i> (s.d.)		0.1 (0.8)
Enthesitis index (0–39), <i>m</i> (s.d.)		4.2 (5.8)
Imaging markers, <i>n</i> (%)		
Radiographic changes as per ACR criteria	108 (13.6)	218 (34.0)
Sacroiliitis features in MRI		
Biological markers		
RF positivity, <i>n</i> (%)	334 (42.1)	
ACPA positivity, <i>n</i> (%)	306 (38.5)	
HLA B27 positivity, <i>n</i> (%)		380 (59.2)
Treatment		
NSAIDs, <i>n</i> (%)	722 (90.9)	597 (93.0)
CSs, <i>n</i> (%)	156 (19.7)	116 (18.1)
DMARDs, <i>n</i> (%)	55 (6.9)	87 (13.6)
Analgesics, <i>n</i> (%)	538 (67.8)	406 (63.2)
Lifestyle factors		
BMI, <i>m</i> (s.d.), kg/m ²	25.0 (4.5)	23.9 (3.9)
Smoker, <i>n</i> (%)	377 (47.5)	234 (36.5)
Alcohol consumer, <i>n</i> (%)	138 (17.4)	97 (15.1)
Health factors		
Rheumatic disease comorbidity index, <i>m</i> (s.d.)	1.1 (1.3)	0.4 (0.7)
Pain measures		
SF-36 bodily pain scale (0–100), <i>m</i> (s.d.)	62.2 (20.4)	56.7 (22.0)
Joint mobilization pain ^a (0–100), <i>m</i> (s.d.)	54.9 (25.8)	
Resting joint pain ^a (0–100), <i>m</i> (s.d.)	37.0 (27.5)	
Back pain ^b (0–100), <i>m</i> (s.d.)		49.8 (27.1)
Night pain ^b (0–100), <i>m</i> (s.d.)		46.8 (30.3)


Only characteristics of participants with measures for all variables at baseline are described. In 16 out of the 810 ESPOIR analytic samples and in 37 out of the 679 DESIR analytic samples, there were one or more missing variables at baseline. ^aJoint mobilization and resting joint pain are measured using a visual analogue scale in the ESPOIR cohort. ^bBack and night pain are measured using a numerical rating scale in the DESIR cohort. *m*: mean, SF-36: 36-item short-form survey.

Results for RA (ESPOIR)

Univariate and all five multivariate models showing the association between covariates and pain variables (namely, SF-36 BP, joint mobilization, and resting joint pain) assessed at inclusion are provided in the supplement (Supplementary Tables S7, S8 and S9, available at *Rheumatology* online). Fig. 1 represents the 10-year


evolution of SF-36 BP (Supplementary Fig. S2 for joint mobilization pain and Supplementary Fig. S3 for resting joint pain, available at *Rheumatology* online) by socio-demographic groups in the fully adjusted model. Correspondingly, evolution of differences in pain score for each year of follow-up are shown in green in Fig. 2 and Supplementary Table S13, available at *Rheumatology*

Fig. 1 Evolution of SF-36 bodily pain by socio-demographic subgroups from inclusion to up to 10 years in RA (ESPOIR cohort)



*P for difference in pain trajectories/evolution (drawn from testing the interactions between socio-demographic factor and slope terms using the Wald test). Analysis adjusted for socio-demographic factors (sex, age, ethnicity, education, professional and marital status assessed at inclusion) and their interaction with slope terms (time, time² and time³), and disease-related (symptom duration, ESR, tender and swollen joint count, presence of radiographic structural lesions, RF positivity, ACPA positivity), treatment (anti-inflammatory and analgesic agents), lifestyle-related (BMI, smoking, and alcohol consumption status) and health factors (rheumatic disease comorbidity index). Disease-related, treatment, lifestyle-related and health factors were time-dependent, with some exceptions (symptom duration and ACPA positivity at baseline and their interactions with slope terms) were used in analysis. The tables beneath the figures indicate the total number of participants by socio-demographic subgroups contributing at least once to the analysis for every 2 years from year 0 to 10. Estimates came from Margins command in STATA. SF-36, short-form 36.

Fig. 2 Evolution of differences in SF-36 bodily pain by socio-demographic subgroups in RA and SpA



Analysis adjusted for socio-demographic factors (sex, age, ethnicity, education, professional and marital status assessed at inclusion) and their interaction with slope terms (time, time² and time³), and disease-related, treatment, lifestyle-related, and health factors. The green line represents the ESPOIR cohort and the red line the DESIR cohort. SF-36, short-form 36

online (Table 2 for joint mobilization and resting joint pain). Pain did not differ by sex at inclusion ($P_{t0} \geq 0.38$ for 3 pain scores). Though differential pain evolution by sex was not evident [P for interaction between sex and slope terms ($P_{\text{trajectory}} \geq 0.05$)], from 2 up to 4 years after inclusion

males, had lower pain scores than females. Pain evolution differed across age; although the youngest tertile had higher pain at inclusion ($\beta = 4.4$, $P = 0.005$ for SF-36 BP), they showed a significant decrease in both SF-36 BP and joint mobilization pain ($P_{\text{trajectory}} < 0.001$ for both) over

TABLE 2 Differences in visual analogue scale pain scores by socio-demographic factors over follow-up in RA

Year	Sex		Age		Ethnicity		Education		Profession		Marital status				
	Female vs male		Tertile 2 vs tertile 1		Others vs Caucasians		Low vs high		Blue-collar vs no job		White-collar vs no job				
	β	(95% CI)	β	(95% CI)	β	(95% CI)	β	(95% CI)	β	(95% CI)	β	(95% CI)			
Joint mobilization pain															
0	-1.5	(-5.0, 1.9)	-5.0	(-8.5, -1.4)	-9.0	(-12.6, -5.4)	-4.4	4.2	(1.0, 7.4)	-5.4	(-13.4, 2.5)	-4.6	(-11.8, 2.7)	1.8	(-1.5, 5.0)
1	1.3	(-1.5, 4.0)	-1.6	(-4.4, 1.2)	-3.1	(-5.9, -0.2)	-0.8	5.8	(3.2, 8.3)	-4.4	(-10.7, 1.9)	-3.6	(-9.3, 2.1)	2.5	(-0.1, 5.0)
2	2.9	(0.0, 5.7)	0.5	(-2.4, 3.4)	0.4	(-2.5, 3.3)	1.3	6.6	(4.0, 9.3)	-3.8	(-10.2, 2.7)	-3.0	(-8.9, 2.9)	2.4	(-0.2, 5.1)
3	3.6	(0.7, 6.5)	1.5	(-1.4, 4.5)	1.9	(-1.1, 4.9)	2.1	6.9	(4.2, 9.6)	-3.4	(-9.9, 3.1)	-2.7	(-8.7, 3.2)	1.9	(-0.8, 4.6)
4	3.6	(0.8, 6.4)	1.8	(-1.1, 4.7)	2.0	(-0.9, 5.0)	2.1	6.7	(4.1, 9.4)	-3.1	(-9.5, 3.2)	-2.6	(-8.4, 3.2)	1.1	(-1.6, 3.7)
5	3.2	(0.3, 6.0)	1.5	(-1.4, 4.4)	1.2	(-1.8, 4.2)	1.5	6.3	(3.6, 8.9)	-2.9	(-9.2, 3.5)	-2.6	(-8.4, 3.1)	0.2	(-2.5, 2.8)
6	2.6	(-0.4, 5.6)	0.9	(-2.1, 4.0)	0.1	(-3.1, 3.2)	0.7	5.6	(2.9, 8.4)	-2.5	(-9.2, 4.2)	-2.7	(-8.7, 3.3)	-0.6	(-3.4, 2.2)
7	2.1	(-1.1, 5.3)	0.3	(-2.9, 3.6)	-0.9	(-4.3, 2.4)	-0.1	5.0	(2.1, 7.9)	-1.9	(-8.9, 5.1)	-2.7	(-9.0, 3.7)	-1.0	(-4.0, 2.1)
8	1.9	(-1.4, 5.2)	0.0	(-3.4, 3.3)	-1.2	(-4.7, 2.2)	-0.4	4.5	(1.5, 7.5)	-0.9	(-8.0, 6.3)	-2.5	(-9.0, 3.9)	-0.7	(-3.8, 2.4)
9	2.3	(-1.2, 5.8)	0.1	(-3.4, 3.6)	-0.3	(-3.9, 3.3)	0.0	4.3	(1.1, 7.4)	0.6	(-7.0, 8.2)	-2.1	(-9.0, 4.7)	0.3	(-2.9, 3.6)
10	3.5	(-1.2, 8.2)	1.0	(-3.7, 5.6)	2.4	(-2.4, 7.2)	1.6	4.5	(0.2, 8.7)	2.7	(-7.7, 13.0)	-1.4	(-10.7, 7.8)	2.4	(-1.9, 6.8)
P_{treat}	0.052		<0.001				0.169	0.301		0.654				0.153	
Resting joint pain															
0	1.2	(-2.0, 4.5)	-0.9	(-4.3, 2.4)	-3.3	(-6.7, 0.0)	-3.0	9.0	(6.0, 12.0)	-4.5	(-12.0, 3.0)	-7.2	(-14.0, -0.3)	1.7	(-1.4, 4.7)
1	2.7	(0.1, 5.3)	0.7	(-1.9, 3.4)	-1.8	(-4.5, 0.8)	1.5	7.4	(5.0, 9.9)	-2.6	(-8.6, 3.4)	-5.2	(-10.7, 0.2)	0.3	(-2.1, 2.7)
2	3.4	(0.7, 6.0)	1.6	(-1.1, 4.4)	-0.8	(-3.6, 1.9)	4.0	6.5	(4.0, 8.9)	-1.5	(-7.5, 4.6)	-3.9	(-9.5, 1.6)	-0.7	(-3.2, 1.8)
3	3.3	(0.6, 6.0)	1.9	(-0.8, 4.7)	-0.2	(-3.0, 2.6)	5.0	5.9	(3.4, 8.4)	-0.9	(-7.0, 5.2)	-3.1	(-8.6, 2.4)	-1.5	(-4.0, 1.1)
4	2.8	(0.2, 5.4)	1.7	(-0.9, 4.4)	0.1	(-2.7, 2.8)	4.9	5.8	(3.3, 8.2)	-0.7	(-6.5, 5.2)	-2.6	(-7.9, 2.8)	-1.9	(-4.4, 0.5)
5	2.0	(-0.6, 4.6)	1.3	(-1.4, 3.9)	0.1	(-2.7, 2.8)	4.0	5.8	(3.4, 8.2)	-0.6	(-6.4, 5.2)	-2.2	(-7.5, 3.1)	-2.1	(-4.6, 0.3)
6	1.1	(-1.6, 3.9)	0.6	(-2.2, 3.4)	-0.1	(-3.0, 2.7)	2.9	6.0	(3.5, 8.5)	-0.4	(-6.4, 5.6)	-1.9	(-7.3, 3.6)	-2.2	(-4.7, 0.4)
7	0.4	(-2.5, 3.2)	0.0	(-3.0, 2.9)	-0.4	(-3.4, 2.6)	1.9	6.3	(3.6, 8.9)	0.1	(-6.1, 6.4)	-1.4	(-7.1, 4.2)	-2.0	(-4.7, 0.7)
8	-0.1	(-3.0, 2.8)	-0.5	(-3.5, 2.4)	-0.8	(-3.8, 2.3)	1.4	6.4	(3.8, 9.1)	1.2	(-5.2, 7.5)	-0.7	(-6.4, 5.0)	-1.7	(-4.4, 1.0)
9	0.0	(-3.0, 3.0)	-0.7	(-3.8, 2.3)	-1.1	(-4.2, 2.1)	1.9	6.3	(3.6, 9.1)	2.9	(-3.7, 9.6)	0.4	(-5.6, 6.4)	-1.3	(-4.2, 1.5)
10	0.8	(-3.4, 4.9)	-0.5	(-4.6, 3.6)	-1.3	(-5.6, 3.0)	3.7	6.0	(2.2, 9.7)	5.7	(-3.4, 14.9)	2.1	(-6.1, 10.2)	-0.9	(-4.7, 2.9)
P_{treat}	0.185		0.330				0.029	0.215		0.518				0.104	

In the RA/ESPOIR cohort: tertile 1 = ≤ 44.5 years, tertile 2 = 44.7–55.2 years and tertile 3 = ≥ 55.3 years. Highlighted values correspond to a P -value < 0.05 . * P for difference in pain trajectories/evolution (drawn from testing the interactions between socio-demographic factor and slope terms using the Wald test). Analysis adjusted for socio-demographic factors (sex, age, ethnicity, education, professional and marital status assessed at inclusion) and their interaction with slope terms (time, time² and time³), and time-dependent disease-related, treatment, lifestyle, and health factors.

follow-up compared with the oldest tertile. No ethnic differences in pain were observed at inclusion ($P_{t0} \geq 0.11$), but, compared with Caucasians, other ethnic groups showed increased SF-36 BP ($P_{\text{trajectory}} = 0.001$) and resting joint pain ($P_{\text{trajectory}} = 0.029$) over follow-up. Education-based differences in pain were present since inclusion (low vs high education $\beta = 3.8$, $P = 0.007$ for SF-36 BP, $\beta = 4.2$, $P = 0.011$ for joint mobilization pain, $\beta = 9.0$, $P < 0.001$ for resting joint pain) without evolutionary changes ($P_{\text{trajectory}} \geq 0.074$). Profession-related differences in pain evolution were not consistent; compared with white-collar workers, those with no job had higher resting joint pain at inclusion ($\beta = 4.5$ for no job and $\beta = -2.7$ for white-collar workers, $P = 0.048$), and increased SF-36 BP ($P_{\text{trajectory}} = 0.029$) in the later years of follow-up.

Results for SpA (DESIR)

Univariate and all five multivariate models showing the association between covariates and pain at inclusion for SF-36 BP, back, and night pain are provided in the supplement (Supplementary Tables S10, S11 and S12, available at *Rheumatology* online). Fig. 3 represents the 6-year evolution of SF-36 BP (Supplementary Fig. S4 for back pain and Supplementary Fig. S5 for night pain, available at *Rheumatology* online) by socio-demographic groups in the fully adjusted model. Correspondingly, evolution of differences in pain score for each year over follow-up are shown in red in Fig. 2 and Supplementary Table S13, available at *Rheumatology* online (Table 3 for back and night pain). Sex differences in pain assessed at inclusion and pain evolution were not significant ($P_{t0} \geq 0.09$ and $P_{\text{trajectory}} \geq 0.32$); however, from 1 up to at least 4 years of follow-up, males had more decrease in pain scores than females. The youngest tertile experienced a larger decrease in pain over follow-up than the oldest tertile ($P_{\text{trajectory}} = 0.048$ for SF-36 BP, $P_{\text{trajectory}} = 0.015$ for back pain). Compared with Caucasians, other ethnic groups had higher pain scores at inclusion ($\beta = 5.6$, $P = 0.021$ for SF-36 BP) that persisted without evolutionary changes ($P_{\text{trajectory}} \geq 0.29$) except for back pain ($P_{\text{trajectory}} = 0.009$). Higher pain since inclusion persisted constantly through follow-up in those with low education ($\beta = 6.0$, $P < 0.001$ for SF-36 BP, $\beta = 6.3$, $P = 0.001$ for back pain and $\beta = 8.0$, $P < 0.001$ for night pain at inclusion; all $P_{\text{trajectory}} \geq 0.167$) compared with those with high education. Compared with singles, couples had higher back ($\beta = 4.7$, $P = 0.019$) and night pain scores ($\beta = 7.1$, $P = 0.001$) at inclusion; nevertheless, they showed reduced pain over follow-up ($P_{\text{trajectory}} \leq 0.004$ for both numerical rating scales). Despite non-significant pain evolution by professional categories ($P_{\text{trajectory}} \geq 0.15$), inconsistently, those with no job had higher back and night pain compared with white-collar workers.

Sensitivity analysis

Supplementary Figs S6 and S7, available at *Rheumatology* online, show the 10- and 6-year evolution of SF-36 bodily pain score by socio-demographic


groups in the fully adjusted model, respectively, for those fulfilling the ACR 1987 criteria in the ESPOIR cohort ($N = 686$) and the ASAS criteria in the DESIR cohort ($N = 470$). Supplementary Fig. S8, available at *Rheumatology* online, correspondingly shows the evolution of differences in pain scores in both cohorts. The pattern of evolution of all pain scores by socio-demographic factors were in concordance with the main analysis (results shown only for SF-36), except that, due to lack of sufficient power, differences in pain as a function of sex and age over follow-up were not evident.

Discussion

This longitudinal study based on two cohorts of patients with early RA (ESPOIR) and early SpA (DESIR) with repeatedly assessed pain over, respectively, 10 and 6 years presented three salient findings. First, socio-demographic disparities based on sex, age, ethnicity and education were important contributors to pain in early (disease duration ≤ 6 months for RA and ≤ 3 years for SpA) and long-standing IRDs. Of these, disparities in ethnicity and education were associated with clinically meaningful differences in pain scores over follow-up in a consistent manner when compared with the minimal clinically important difference in SF-36 BP score in RA corresponding to 4.9 [34]. Second, differences in pain evolution as a function of demographic factors emerged while transitioning from early to long-standing disease; those who were older at the early disease phase, females, and non-Caucasians, although having similar pain levels to their counterparts during early phases of disease, reported higher pain during the disease course. Third, the impact of social factors on pain occurs much earlier to disease-phase transitioning. Educational disparities did not catalyse changes in pain level through the disease course; the higher pain in those with low education was present from the early phases of disease. Associations between marital status and pain, and between professional status and pain were not consistent.

The present study, compared pain among socio-demographic groups at inclusion when participants were biologic DMARD-naïve and throughout the disease course, after accounting for disease-specific, treatment, lifestyle and health characteristics. Importantly, the availability of repeatedly assessed data from early disease up to a span of 10 and 6 years, respectively, for RA and SpA, allowed us to account for the time-varying nature of pain and other covariates, thus, giving an insight into the variations in the association between socio-demographic factors and pain in both early and long-standing disease. As far as we know, this is the first study that has examined pain evolution in IRDs among socio-economically disparate groups. By considering the evolution of three pain scores for each disease, an overall view (limiting biases related to pain assessment instruments) was obtained. Sensitivity analysis done by restricting the analysis to those who

Fig. 3 Evolution of SF-36 bodily pain by socio-demographic subgroups from inclusion to up to 6 years in SpA (DESIR cohort)



* *P* for difference in pain trajectories/evolution (drawn from testing the interactions between socio-demographic factor and slope terms using Wald test). Analysis adjusted for socio-demographic factors (sex, age, ethnicity, education, professional and marital status assessed at inclusion) and their interaction with slope terms (time, time², and time³), and disease-related (symptom duration, CRP, arthritis, synovitis, and enthesitis indices, presence of sacroiliitis, human leukocyte antigen B27 positivity), treatment (anti-inflammatory and analgesic agents), lifestyle-related (BMI, smoking, and alcohol consumption status), and health factors (rheumatic disease comorbidity index). Disease-related, treatment, lifestyle-related and health factors were time-dependant with some exceptions (symptom duration, presence of sacroiliitis and human leukocyte antigen B 27 positivity at baseline and their interaction with slope terms) were used in analysis. The tables beneath the figures indicate the total number of participants by socio-demographic sub-groups contributing at least once to the analysis by every year from year 0 to 6. Estimates came from Margins command in STATA.

TABLE 3 Differences in numerical rating scale pain scores by socio-demographic factors over follow-up in SpA

Year	β	(95% CI)	Sex			Age			Ethnicity			Education			Profession			Marital status								
			Female vs male			Tertile 2 vs tertile 1			Tertile 3 vs tertile 1			Others vs Caucasians			Low vs high			Blue-collar vs no job			White-collar vs no job			Single vs couples		
			β	(95% CI)	P	β	(95% CI)	P	β	(95% CI)	P	β	(95% CI)	P	β	(95% CI)	P	β	(95% CI)	P	β	(95% CI)	P			
0	3.2	(-0.5, 6.9)																								
1	3.4	(0.4, 6.4)	0.8	(-2.9, 4.5)	-0.7	(-4.5, 3.2)	4.7	(-0.1, 9.5)	13.2	(7.5, 19.0)	6.3	(2.6, 10.0)	2.9	(-4.1, 9.8)	1.9	(-3.5, 7.3)	-4.7	(-8.6, -0.8)								
2	3.7	(0.6, 6.8)	2.7	(-1.1, 6.5)	1.9	(-2.1, 5.9)	3.4	(-1.7, 8.5)	4.7	(-0.1, 9.5)	6.1	(3.0, 9.1)	-0.8	(-6.5, 4.8)	-1.1	(-5.5, 3.4)	-0.7	(-3.8, 2.5)								
3	4.1	(0.9, 7.3)	3.3	(-0.6, 7.2)	4.4	(0.3, 8.6)	6.1	(0.8, 11.4)	3.4	(-1.7, 8.5)	6.6	(3.5, 9.7)	-3.0	(-8.9, 2.8)	-3.6	(-8.2, 1.1)	1.5	(-1.7, 4.8)								
4	4.4	(0.7, 8.1)	3.1	(-1.3, 7.6)	6.1	(1.5, 10.8)	9.5	(3.4, 15.6)	6.1	(0.8, 11.4)	7.4	(4.2, 10.7)	-4.0	(-10.1, 2.1)	-5.0	(-9.8, -0.3)	2.4	(-1.0, 5.8)								
5	4.6	(0.7, 8.4)	2.8	(-1.9, 7.5)	6.2	(1.3, 11.1)	10.6	(4.2, 17.0)	9.5	(3.4, 15.6)	8.1	(4.4, 11.8)	-4.0	(-10.9, 2.9)	-5.0	(-10.4, 0.5)	2.7	(-1.2, 6.6)								
6	4.4	(-0.6, 9.4)	2.9	(-3.3, 9.1)	4.0	(-2.5, 10.4)	6.1	(-2.5, 14.7)	10.6	(4.2, 17.0)	8.2	(4.3, 12.1)	-3.4	(-10.7, 4.0)	-2.8	(-8.6, 3.0)	2.9	(-1.2, 7.0)								
P_{trend}	0.924		0.015		0.009		0.733		0.009		0.151		0.167		0.298		0.004									
0	2.5	(-1.6, 6.6)	0.2	(-4.8, 5.3)	-1.6	(-6.8, 3.7)	10.7	(4.2, 17.1)	10.7	(4.2, 17.1)	8.0	(3.9, 12.1)	2.6	(-5.2, 10.4)	0.9	(-5.1, 6.9)	-7.1	(-11.5, -2.8)								
1	3.6	(0.2, 7.0)	-1.4	(-5.5, 2.8)	-0.1	(-4.4, 4.3)	6.2	(0.8, 11.7)	6.2	(0.8, 11.7)	5.5	(2.1, 8.9)	0.5	(-5.9, 6.9)	-1.9	(-6.9, 3.1)	-1.4	(-4.9, 2.2)								
2	4.4	(1.0, 7.9)	-1.0	(-5.3, 3.2)	1.2	(-3.3, 5.6)	6.4	(0.8, 12.0)	6.4	(0.8, 12.0)	5.4	(2.0, 8.9)	-1.4	(-8.0, 5.1)	-4.4	(-9.5, 0.7)	1.0	(-2.6, 4.7)								
3	4.8	(1.3, 8.4)	0.3	(-4.0, 4.7)	2.4	(-2.2, 6.9)	8.9	(3.0, 14.7)	8.9	(3.0, 14.7)	6.8	(3.2, 10.4)	-3.2	(-9.9, 3.6)	-6.3	(-11.5, -1.0)	1.4	(-2.4, 5.1)								
4	4.7	(0.7, 8.7)	1.8	(-3.0, 6.7)	3.5	(-1.6, 8.6)	11.3	(4.7, 18.0)	11.3	(4.7, 18.0)	8.6	(4.6, 12.7)	-4.4	(-12.0, 3.1)	-7.1	(-13.0, -1.1)	1.0	(-3.3, 5.3)								
5	3.8	(-0.4, 8.0)	2.5	(-2.6, 7.6)	4.8	(-0.6, 10.2)	11.4	(4.5, 18.4)	11.4	(4.5, 18.4)	9.9	(5.6, 14.1)	-5.0	(-13.0, 3.0)	-6.4	(-12.7, -0.1)	1.2	(-3.3, 5.7)								
6	2.1	(-3.3, 7.5)	1.4	(-5.3, 8.1)	6.3	(-0.7, 13.2)	6.9	(-2.4, 16.2)	6.9	(-2.4, 16.2)	9.5	(3.9, 15.1)	-4.8	(-15.3, 5.7)	-3.8	(-12.4, 4.9)	3.4	(-2.4, 9.2)								
P_{trend}	0.608		0.269		0.294		0.167		0.294		0.167		0.298		0.001		0.001									

In the SpA/DESIR cohort: tertile 1 = <29.4 years, tertile 2 = 29.4-37.6 years, tertile 3 = ≥37.7 years. Highlighted values correspond to a P -value < 0.05. * P for difference in pain trajectories/evolution (drawn from testing the interactions between socio-demographic factor and slope terms using the Wald test). Analysis adjusted for socio-demographic factors (sex, age, ethnicity, education, professional and marital status assessed at inclusion) and their interaction with slope terms (time, time² and time³), and time-dependent disease-related, treatment, lifestyle, and health factors.

fulfilled diagnostic criteria was also in concordance with the above findings.

Sex-attributed differences in pain [16, 24], disease activity [35], treatment response [36], and quality of life [37] are known in IRDs. In accordance with past findings [15, 38], women in this study with SpA reported higher crude pain scores compared with men (Supplementary Tables S10–S12, available at *Rheumatology* online). However, adjustment for disease-specific characteristics (inflammatory and clinical markers) attenuated the observed sex differences in pain in early IRD. With ongoing disease and treatment, a lesser improvement in pain was seen for a short while in women with RA before their pain scores decreased further to plateau with those of men. Confirming our findings, no sex differences in pain were reported in early IRD studies [18, 26], whereas improvement in pain was better among men in long-standing IRDs [15, 25].

The impact of age on pain was variable in early and long-standing IRDs. In early RA, our study findings—higher pain in younger persons—were in disaccord with past studies reporting no association between pain and age [17, 26]. Discrepancies might be due to differences in adjustment for covariates, as even in our study, association between age and pain was revealed only after adjustment for disease-related factors, lifestyle factors, and comorbidities (Supplementary Tables S7–S9, available at *Rheumatology* online). In long-standing disease, our study findings were congruent with those of past research [13, 14]—increasing pain with ageing. With disease continuum and appropriate treatment initiation, younger persons experienced more decrease in pain than older persons, thereby, establishing an age-based pain gap.

Ethnic minorities reported worse levels for most rheumatological outcomes [11, 19, 39]. In this study, compared with Caucasians, all measures except joint mobilization pain were higher among other ethnic groups. Predominantly, the disease-specific inflammation-mediated heightened pain sensitivity of affected joints mediated joint mobilization pain more than the more general non-inflammatory central pain mechanisms [40], and thus did not differ across ethnic groups. Factors yet revealed may increase the susceptibility of ethnic minorities to non-inflammatory central pain mechanisms.

Across the spectrum of IRDs, low levels of socio-economic indicators like education, occupation, income or home ownership were often associated with increased pain [20]. In this study, education-based pain differences were present even in the early disease phase and persisted throughout. This is in accordance with antecedent studies that demonstrated higher pain in those with low education in both early [41] and long-standing disease [11, 21, 22, 42]. Some showed a gradient in the association between years of education and pain [11]. This study failed to demonstrate consistent association between pain and profession, unlike the antecedent studies [43]. Discrepancies might have risen due to

differences in the classification of professional categories and the use of socio-economic indicators between the studies. Family resources like income and house ownership predicted pain better than occupational status [21, 44].

Social environment, both quantitatively (in terms of the extent of the social network) and qualitatively (in terms of the emotional and necessary support provided by the extended family and friends [42] or marital life quality [12, 45]), play important roles in the long-term pain outcome in IRDs. In our study, lack of association between pain and marital status in RA could have stemmed from the fact that assessment of marital status is not synonymous to marital quality, a better predictor of pain. In early SpA, couples reported more back pain, eventually coping as well as those single, widowed or separated; given a fairly younger age onset in SpA, family commitments may have increased the pain susceptibility in early disease.

Complex and interacting multiple mechanisms underlie the socio-demographic differences in pain. First, biological mechanisms can result in altered pain sensitivity and pain modulation; hormonal differences between sexes [46], various ethnic origins [47], age-related degenerative changes in the nervous system [48], and associated comorbidities [48] can contribute to neurobiological alterations affecting pain perception. Second, psychological mechanisms (by affecting mood, anxiety and depression, comprehension, acceptance and adherence to health-promoting behaviours) and the utilization of coping strategies can influence pain responsivity [46, 47, 49]. Women [46], ethnic minorities [47], those at socio-economic disadvantage [50] and with poor marital quality [49] often rely on passive coping strategies and indulge in maladaptive pain behaviour and pain catastrophizing [8, 9]. Third, socio-cultural mechanisms such as pain-, religion-, and health-related beliefs [46, 47] and sex, age, and ethnic differences in societal expected roles and accepted behaviours can affect pain [51].

Limitations included non-availability of information regarding the characteristics, location, and mechanisms of pain. Pain variables were collected based on the self-report of pain over a short time span (past 8 days) that may not exactly reflect past pain experiences. However, pain levels reported over short time spans are more reliable with regards to the accuracy of reporting rather than compared with pain reported over the long term. Also, the data is collected in the same manner for all participants at all time points over follow-up, and any inaccuracy in measure will be random. Overall, this could be assumed to be a good representation of the pain of these participants over the years. Pain coping strategies and behaviours, and the quality and quantity of social support, which can influence pain outcomes, were unavailable. Non-pharmacological pain interventions were not assessed. Due to lack of details regarding monetary resources per person, the impact of socio-economic disadvantage on pain evolution has been insufficiently explored. Finally,

comorbidities and medication use were self-reported and are subject to recall bias.

Persistent pain in IRDs despite adequate access to advanced treatment leads to patient dissatisfaction and secondarily augments the health burden. Understanding the evolution of pain in IRDs and its associated factors seems important for identifying those with poor pain prognosis and imparting effective multimodal treatment. Sex, age, ethnic origin, and education play important roles in the pain experienced in early and long-standing IRDs.

Acknowledgements

These results were presented at the 33e congrès français de Rhumatologie organized by the French Society of Rheumatology (France) as a preregistered oral presentation (O.129). The authors are grateful to all participants of both the ESPOIR and DESIR cohorts. ESPOIR COHORT: an unrestricted grant for the first 5 years was allocated from Merck Sharp and Dohme (MSD). Part of the biological database support came from two additional grants from INSERM. The ESPOIR cohort study is also supported by the French Society of Rheumatology, Pfizer, Abbvie, Lilly, and more recently Fresenius and Biogen. Additionally, we wish to thank Nathalie Rincheval (Montpellier), who did expert monitoring and data management, and all the investigators who recruited and followed the patients (F. Berenbaum, Paris-Saint Antoine; M.C. Boissier, Paris-Bobigny; A. Cantagrel, Toulouse; B. Combe, Montpellier; M. Dougados, Paris-Cochin; P. Fardellone et P. Boumier, Amiens; B. Fautrel, Paris-La Pitié; R.M. Flipo, Lille; Ph. Goupille, Tours; F. Liote, Paris-Lariboisière; O. Vittecoq, Rouen; X. Mariette, Paris Bicetre; P. Dieude, Paris Bichat; A. Saraux, Brest; T.Schaefferbeke, Bordeaux; J. Sibilia, Strasbourg). DESIR COHORT: the Département de la Recherche Clinique et du Développement de l'Assistance Publique-Hôpitaux de Paris sponsored the DESIR cohort. This study was conducted under the umbrella of the French Society of Rheumatology and INSERM (Institut National de la Santé et de la Recherche Médicale). The database management is performed in the Department of Epidemiology and Biostatistics (Professor Paul Landais, D.I.M., Nîmes, France). For the first 10 years of the follow-up of the recruited patients, an unrestricted grant from Pfizer was allocated. We also thank colleagues at the various regional participating centres: Professor M. Dougados (Paris-Cochin B), Professor A. Kahan (Paris-Cochin A), Professor P. Dieudé (Paris-Bichat), Professor L. Gossec (Paris-Pitié-Salpêtrière), Professor F. Berenbaum (Paris-Saint Antoine), Professor P. Claudepierre (Créteil), Professor M. Breban (Boulogne Billancourt), Dr B. Saint-Marcoux (Aulnay-sous-Bois), Professor P. Goupille (Tours), Professor J.-F. Maillfert (Dijon), Dr E. Denis (Le Mans), Professor D. Wendling (Besançon), Professor B. Combe (Montpellier), Professor L. Euler-Ziegler (Nice), Professor P. Orcel, Professor P. Richette (Paris-Lariboisière), Professor P. Lafforgue (Marseille), Dr P. Boumier (Amiens), Professor M. Soubrier (Clermont-Ferrand), Dr N. Mehzen (Bordeaux), Professor D. Loeuille (Nancy), Professor R.-M.

Flipo (Lille), Professor A. Saraux (Brest), Dr S. Pavy (Kremlin Bicêtre), Professor A. Cantagrel (Toulouse), Professor O. Vittecoq (Rouen). We also thank the URC-CIC Paris Centre for the coordination and monitoring of the study. S.K., C.R., A.D. and A.M. developed the hypothesis and study design. S.K. and A.D. performed statistical analysis. S.K. and A.D. wrote the first and successive drafts of the manuscript. All authors contributed to review of manuscript and approved the final version to be published. S.K., A.D. and A.M. had full access to the data and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Disclosure statement: The authors have declared no conflicts of interest.

Data availability statement

The datasets generated and/or analysed during the current study are not publicly available due to consent restrictions. Programming codes used for statistical analysis during the current study are available from the corresponding author upon reasonable request.

Supplementary data

Supplementary data are available at *Rheumatology* online.

References

- Walsh DA, McWilliams DF. Mechanisms, impact and management of pain in rheumatoid arthritis. *Nat Rev Rheumatol* 2014;10:581–92.
- Bidad K, Gracey E, Hemington KS *et al.* Pain in ankylosing spondylitis: a neuro-immune collaboration. *Nat Rev Rheumatol* 2017;13:410–20.
- Carpenter L, Barnett R, Mahendran P *et al.* Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis. *Semin Arthritis Rheum* 2020;50:209–19.
- Carpenter L, Nikiphorou E, Kiely PDW *et al.* Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis. *Rheumatology (Oxford)* 2020;59:2381–91.
- Matcham F, Scott IC, Rayner L *et al.* The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. *Semin Arthritis Rheum* 2014;44:123–30.
- Yang X, Fan D, Xia Q *et al.* The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis. *Qual Life Res* 2016;25:2711–23.
- McWilliams DF, Dawson O, Young A *et al.* Discrete trajectories of resolving and persistent pain in people with rheumatoid arthritis despite undergoing treatment

- for inflammation: results from three UK cohorts. *J Pain* 2019;20:716–27.
- 8 Vergne-Salle P, Pouplin S, Trouvin AP *et al.* The burden of pain in rheumatoid arthritis: impact of disease activity and psychological factors. *Eur J Pain* 2020;24:1979–89.
 - 9 Perrot S, Dieude P, Perocheau D, Allanore Y. Comparison of pain, pain burden, coping strategies, and attitudes between patients with systemic sclerosis and patients with rheumatoid arthritis: a cross-sectional study. *Pain Med* 2013;14:1776–85.
 - 10 Trouvin AP, Curis E, Nicolis I, Beller C, Perrot S. Experience of pain is correlated to treatment profile in patients with rheumatoid arthritis. Differentiating 5 clusters of patients in a national cohort of 1100 women with rheumatoid arthritis. *Joint Bone Spine* 2020;87:675–6.
 - 11 Wolfe F, Michaud K. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. *J Rheumatol* 2007;34:1674–83.
 - 12 Waltz M, Kriegel W, van't Pad Bosch P. The social environment and health in rheumatoid arthritis: marital quality predicts individual variability in pain severity. *Arthritis Care Res* 1998;11:356–74.
 - 13 McWilliams DF, Walsh DA. Factors predicting pain and early discontinuation of tumour necrosis factor- α -inhibitors in people with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *BMC Musculoskelet Disord* 2016;17:337.
 - 14 Mogard E, Lindqvist E, Bremander A, Bergman S. Risk factors for development and persistence of chronic widespread pain in spondyloarthritis: a population-based two-year follow-up study. *Scand J Rheumatol* 2019;48:460–8.
 - 15 Barnabe C, Bessette L, Flanagan C *et al.* Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis. *J Rheumatol* 2012;39:1221–30.
 - 16 Swinnen TW, Westhovens R, Dankaerts W, de Vlam K. Widespread pain in axial spondyloarthritis: clinical importance and gender differences. *Arthritis Res Ther* 2018;20:156.
 - 17 McWilliams DF, Zhang W, Mansell JS *et al.* Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study. *Arthritis Care Res (Hoboken)* 2012;64:1505–13.
 - 18 Ten Klooster PM, Vonkeman HE, Oude Voshaar MA *et al.* Predictors of satisfactory improvements in pain for patients with early rheumatoid arthritis in a treat-to-target study. *Rheumatology (Oxford)* 2015;54:1080–6.
 - 19 Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. *J Rheumatol* 2007;34:1475–9.
 - 20 Vilen L, Baldassari AR, Callahan LF. Socioeconomic burden of pain in rheumatic disease. *Clin Exp Rheumatol* 2017;35(Suppl 107):26–31.
 - 21 Baldassari AR, Cleveland RJ, Jonas BL *et al.* Socioeconomic disparities in the health of African Americans with rheumatoid arthritis from the southeastern United States. *Arthritis Care Res (Hoboken)* 2014;66:1808–17.
 - 22 Baldassari AR, Cleveland RJ, Luong MN *et al.*; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis. Socioeconomic factors and self-reported health outcomes in African Americans with rheumatoid arthritis from the Southeastern United States: the contribution of childhood socioeconomic status. *BMC Musculoskelet Disord* 2016;17:10.
 - 23 Andersson ML, Svensson B, Bergman S. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. *J Rheumatol* 2013;40:1977–85.
 - 24 Ahlstrand I, Thyberg I, Falkmer T, Dahlström Ö, Björk M. Pain and activity limitations in women and men with contemporary treated early RA compared to 10 years ago: the Swedish TIRA project. *Scand J Rheumatol* 2015;44:259–64.
 - 25 Andersson MLE, Forslind K, Hafstrom I; BARFOT Study Group. Patients with early rheumatoid arthritis in the 2000s have equal disability and pain despite less disease activity compared with the 1990s: data from the BARFOT study over 8 years. *J Rheumatol* 2017;44:723–31.
 - 26 Dobkin PL, Liu A, Abrahamowicz M *et al.* Predictors of pain for patients with early inflammatory polyarthritis. *Arthritis Care Res (Hoboken)* 2013;65:992–9.
 - 27 Combe B, Rincheval N. Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR. *Joint Bone Spine* 2015;82:13–7.
 - 28 Dougados M, Etcheto A, Molto A *et al.*; DESIR cohort. Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: the DESIR cohort. *Joint Bone Spine* 2015;82:345–51.
 - 29 Ruta DA, Hurst NP, Kind P, Hunter M, Stubbings A. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). *Br J Rheumatol* 1998;37:425–36.
 - 30 Linde L, Sørensen J, Ostergaard M, Hørslev-Petersen K, Hetland ML. Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. *J Rheumatol* 2008;35:1528–37.
 - 31 Sendlbeck M, Araujo EG, Schett G, Englbrecht M. Psychometric properties of three single-item pain scales in patients with rheumatoid arthritis seen during routine clinical care: a comparative perspective on construct validity, reproducibility and internal responsiveness. *RMD Open* 2015;1:e000140.
 - 32 Arnett FC, Edworthy SM, Bloch DA *et al.* The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315–24.
 - 33 England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the rheumatic disease comorbidity index. *Arthritis Care Res (Hoboken)* 2015;67:865–72.

- 34 Ward MM, Guthrie LC, Alba MI. Clinically important changes in short form 36 health survey scales for use in rheumatoid arthritis clinical trials: the impact of low responsiveness. *Arthritis Care Res (Hoboken)* 2014;66:1783–9.
- 35 Sokka T, Toloza S, Cutolo M *et al.* Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. *Arthritis Res Ther* 2009;11:R7.
- 36 Austad C, Kvien TK, Olsen IC, Uhlig T. Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register. *Ann Rheum Dis* 2015;74:148–55.
- 37 Webers C, Essers I, Ramiro S *et al.* Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. *Rheumatology (Oxford)* 2016;55:419–28.
- 38 Mogard E, Bremander A, Lindqvist E, Bergman S. Prevalence of chronic widespread pain in a population-based cohort of patients with spondyloarthritis – a cross-sectional study. *BMC Rheumatol* 2018;2:11.
- 39 Eberly L, Richter D, Comerchi G *et al.* Psychosocial and demographic factors influencing pain scores of patients with knee osteoarthritis. *PLoS One* 2018;13:e0195075.
- 40 Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. *Arthritis Res Ther* 2011;13:211.
- 41 Jiang X, Sandberg ME, Saevarsdottir S *et al.* Higher education is associated with a better rheumatoid arthritis outcome concerning for pain and function but not disease activity: results from the EIRA cohort and Swedish rheumatology register. *Arthritis Res Ther* 2015;17:317.
- 42 Evers AW, Kraaimaat FW, Geenen R, Jacobs JW, Bijlsma JW. Pain coping and social support as predictors of long-term functional disability and pain in early rheumatoid arthritis. *Behav Res Ther* 2003;41:1295–310.
- 43 Andersson ML, Bergman S, Soderlin MK. The effect of socioeconomic class and immigrant status on disease activity in rheumatoid arthritis: data from BARFOT, a multi-centre study of early RA. *Open Rheumatol J* 2013;7:105–11.
- 44 Yang G, Bykerk VP, Boire G *et al.*; The CATCH Investigators. Does socioeconomic status affect outcomes in early inflammatory arthritis? Data from a Canadian multisite suspected rheumatoid arthritis inception cohort. *J Rheumatol* 2015;42:46–54.
- 45 Reese JB, Somers TJ, Keefe FJ, Mosley-Williams A, Lumley MA. Pain and functioning of rheumatoid arthritis patients based on marital status: is a distressed marriage preferable to no marriage? *J Pain* 2010;11:958–64.
- 46 Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. *Br J Anaesth* 2013;111:52–8.
- 47 Campbell CM, Edwards RR. Ethnic differences in pain and pain management. *Pain Manag* 2012;2:219–30.
- 48 El Tumi H, Johnson MI, Dantas PBF, Maynard MJ, Tashani OA. Age-related changes in pain sensitivity in healthy humans: a systematic review with meta-analysis. *Eur J Pain* 2017;21:955–64.
- 49 Robles TF, Slatcher RB, Trombello JM, McGinn MM. Marital quality and health: a meta-analytic review. *Psychol Bull* 2014;140:140–87.
- 50 Poleshuck EL, Green CR. Socioeconomic disadvantage and pain. *Pain* 2008;136:235–8.
- 51 Wandner LD, Scipio CD, Hirsh AT, Torres CA, Robinson ME. The perception of pain in others: how gender, race, and age influence pain expectations. *J Pain* 2012;13:220–7.